The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE Trial Sub-study 

References

• Schulze MB, Hu FB. Primary prevention of diabetes: what can be done and how much can be prevented? Annu Rev Public Health 2005;26:445–67
   PubMed Web of Science ®Google Scholar
• Laakso M. Lipids and lipoproteins as risk factors for coronary heart disease in non-insulin-dependent diabetes mellitus. Ann Med 1996;28:341–5
   PubMed Web of Science ®Google Scholar
• Nicholls S, Lundman P. The emerging role of lipoproteins in atherogenesis: beyond LDL cholesterol. Semin Vasc Med 2004;4:187–95
   PubMedGoogle Scholar
• Steiner G. The dyslipoproteinemias of diabetes. Atherosclerosis 1994;110(Suppl):S27–S33
   Google Scholar
• Williams PT, Superko HR, Haskell WL, et al. Smallest LDL particles are most strongly related to coronary disease progression in men. Arterioscler Thromb Vasc Biol 2003;23:314–21
   PubMed Web of Science ®Google Scholar
• Vakkilainen J, Steiner G, Ansquer JC, et al. on behalf of the DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003;107:1733–7
   Google Scholar
• Lamarche B, St-Pierre AC, Ruel IL, et al. A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol 2001;17:859–65
   PubMed Web of Science ®Google Scholar
• Tkac I, Kimball BP, Lewis G, et al. The severity of coronary atherosclerosis in type 2 diabetes mellitus is related to the number of circulating triglyceride-rich lipoprotein particles. Arterioscler Thromb Vasc Biol 1997;17:3633–8
   PubMed Web of Science ®Google Scholar
• Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004;27:1496–504
   PubMed Web of Science ®Google Scholar
• Skeggs JW, Morton RE. LDL and HDL enriched in triglyceride promote abnormal cholesterol transport. J Lipid Res 2002;43:1264–74
   PubMed Web of Science ®Google Scholar
• Kulkarni KR, Garber DW, Marcovina SM, et al. Quantification of cholesterol in all lipoprotein classes by the VAP-II method. J Lipid Res 1994;35:159–68
   PubMed Web of Science ®Google Scholar
• St-Pierre AC, Cantin B, Dagenais GR, et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005;25: 553–9
   Google Scholar
• Chu JW, Abbasi F, Kulkarni KR, et al. Multiple lipoprotein abnormalities associated with insulin resistance in healthy volunteers are identified by the vertical auto profile-II methodology. Clin Chem 2003;49(6 Pt 1):1014–7
   Google Scholar
• Despres JP, Lemieux I, Robins SJ. Role of fibric acid derivatives in the management of risk factors for coronary heart disease. Drugs 2004;64:2177–98
   Google Scholar
• Taskinen MR. LDL-cholesterol, HDL-cholesterol or triglycerides – which is the culprit? Diabetes Res Clin Pract 2003;61 (Suppl 1):S19–S26
   PubMedGoogle Scholar
• Fruchart JC, Duriez P. HDL and triglyceride as therapeutic targets. Curr Opin Lipidol 2002;13:605–16
   PubMed Web of Science ®Google Scholar
• Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003;171:1–13
   PubMed Web of Science ®Google Scholar
• Miller M, Dobs A, Yuan Z, et al. Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C. Curr Med Res Opin 2004;20:1087–94
   PubMed Web of Science ®Google Scholar
• Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study [The Pioglitazone 027 Study Group]. Clin Ther 2000;22:1395–409
   PubMed Web of Science ®Google Scholar
• Sunayama S, Watanabe Y, Ohmura H, et al. Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. Atherosclerosis 1999;146:187–93
   PubMed Web of Science ®Google Scholar
• Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434–44
   PubMed Web of Science ®Google Scholar
• Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035–8
   PubMed Web of Science ®Google Scholar
• Panzram G. Mortality and survival in type 2 (non-insulin- dependent) diabetes mellitus. Diabetologia 1987;30:123–31
   PubMed Web of Science ®Google Scholar
• Haffner SM. Diabetes, hyperlipidemia, and coronary artery disease. Am J Cardiol 1999;83:17F–21F
   Google Scholar
• Ballantyne CM, Hoogeveen RC. Role of lipid and lipoprotein profiles in risk assessment and therapy. Am Heart J 2003;146:227–33
   PubMed Web of Science ®Google Scholar
• Jiang R, Schulze MB, Li T, et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 2004;27:1991–7
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• Stein EA, Black DM. Lipoprotein changes with statins. Curr Atheroscler Rep 2002;4:14–8
   PubMedGoogle Scholar
• Hunninghake DB, Ballantyne CM, Maccubbin DL, et al. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clin Ther 2003;25:1670–86
   PubMed Web of Science ®Google Scholar
• Geiss HC, Schwandt P, Parhofer KG. Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipoproteinemia. Exp Clin Endocrinol Diabetes 2002;110:182–7
   Google Scholar
• Dallinga-Thie GM, Berk-Planken II, Bootsma AH, et al. Diabetes Atorvastatin Lipid Intervention (DALI) Study Group. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides. Diabetes Care 2004;27: 1358–64
   Google Scholar
• Vega GL, Ma PT, Cater NB, et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2003;91:956–60
   PubMed Web of Science ®Google Scholar
• Vega GL, Grundy SM. Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men. Am J Cardiol 1998;81:36B–42B
   Google Scholar
• Ayyobi AF, Brunzell JD. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. Am J Cardiol 2003;92:27J–33J
   Google Scholar
• Tenenbaum A, Fisman EZ. Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both? Cardiovasc Diabetol 2004;3:10
   PubMedGoogle Scholar
• Stein E, Plotkin D, Bays H, et al. Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia. Am J Cardiol 2000;86:406–11
   PubMed Web of Science ®Google Scholar
• Miller M, Dolinar C, Cromwell W, et al. Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia. Am J Cardiol 2001;87:232–4
   PubMed Web of Science ®Google Scholar
• Hodis HN. Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis. Circulation 1999;99:2852–4
   PubMed Web of Science ®Google Scholar
• Thompson GR. Angiographic evidence for the role of triglyceride-rich lipoproteins in progression of coronary artery disease. Eur Heart J 1998;19(Suppl H):H31–H36
   Google Scholar
• Krauss RM. Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease. Am Heart J 1987;113:578–82
   PubMed Web of Science ®Google Scholar
• Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996;16:697–704
   Google Scholar
• Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 2004;6:381–7
   PubMedGoogle Scholar
• Lu W, Resnick HE, Jablonski KA, et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care 2003;26:16–23
   PubMed Web of Science ®Google Scholar
• Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 2002;106:2526–9
   PubMed Web of Science ®Google Scholar
• Alexander CM, Landsman PB, Teutsch SM, et al. [Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP)]. NCEP- defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52: 1210–4
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005;28(Suppl 1):S4–S36
   PubMedGoogle Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. [National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association]. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–39
   Google Scholar